The PNPLA3 I148M variant in humans has been found to increase susceptibility to the whole spectrum of hepatic damage associated with NAFLD while it also promotes hepatic fat accumulation without directly affecting adiposity and insulin resistance to a significant extent [30]. The gene discussed is PNPLA3; the disease is metabolic dysfunction-associated steatotic liver disease.